Last reviewed · How we verify
furosemide and hypertonic saline solution
Furosemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, leading to increased urine production and decreased fluid volume.
Furosemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, leading to increased urine production and decreased fluid volume. Used for Edema associated with congestive heart failure, cirrhosis of the liver, and a nephrotic syndrome in adults. Hypertensive emergency including hypertensive encephalopathy, hypertensive intracerebral hemorrhage, and malignant hypertension..
At a glance
| Generic name | furosemide and hypertonic saline solution |
|---|---|
| Sponsor | Aspirus Heart and Vascular Institute-Research and Education |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter 2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This results in a decrease in blood volume and a subsequent decrease in blood pressure. The increased urine production also helps to reduce fluid overload in conditions such as heart failure and pulmonary edema.
Approved indications
- Edema associated with congestive heart failure, cirrhosis of the liver, and a nephrotic syndrome in adults. Hypertensive emergency including hypertensive encephalopathy, hypertensive intracerebral hemorrhage, and malignant hypertension.
Common side effects
- Dehydration
- Electrolyte imbalance
- Hypokalemia
- Hypomagnesemia
- Hypocalcemia
- Hypotension
- Dizziness
- Headache
- Nausea
- Vomiting
Key clinical trials
- Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study (PHASE4)
- Nebulized Furosemide, Heparin, Hypertonic Saline in Mechanically Ventilated Acute Respiratory Distress Syndrome Adult Patients (NA)
- SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF (PHASE4)
- Hypertonic Saline Therapy in Ambulatory Heart Failure Unit. (PHASE3)
- Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites (PHASE2)
- Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) (PHASE3)
- Tolvaptan for In-hospital Hyponatremia (PHASE2)
- Metabolic Effects of Furosemide +HSS in Refractory Ascites (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: